Correlation of Heterozygote risk, Pathological risk and lifetime risk with Clinicopathologic Features in Iranian breast cancer patients
Author(s) -
Sahar Ardalan Khales,
Mahtab Dastpak,
Fatemeh Homayee Shandiz,
Narjes Forouzanfar,
Ariane SadrNabavi
Publication year - 2017
Publication title -
the cancer press
Language(s) - English
Resource type - Journals
ISSN - 2476-3748
DOI - 10.15562/tcp.45
Subject(s) - breast cancer , medicine , correlation , heterozygote advantage , pathological , cancer , oncology , genetics , biology , allele , mathematics , gene , geometry
www.thecancerpress.com Corresponding Author E-Mail: sadrnabavia@mums.ac.ir 67 References 1. Mousavi SM, Montazeri A, Mohagheghi MA, Jarrahi AM, Harirchi I, Najafi M, et al. Breast cancer in Iran: an epidemiological review. The breast journal. 2007;13(4):383-91. 2. Harirchi I, Kolahdoozan S, Karbakhsh M, Chegini N, Mohseni S, Montazeri A, et al. Twenty years of breast cancer in Iran: downstaging without a formal screening program. Annals of oncology. 2010;22(1):93-7. 3. Claus EB, Schildkraut JM, Thompson WD, Risch NJ. The genetic attributable risk of breast and ovarian cancer. Cancer. 1996;77(11):2318-24. 4. Antoniou A, Pharoah P, Narod S, Risch HA, Eyfjord JE, Hopper J, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. The American Journal of Human Genetics. 2003;72(5):1117-30. Original Article Vol. 3, No. 2, jun, 2017 Vol 3, No 2, Jun, 2017, P 67-73 DOI, 10.15562/tcp.45
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom